Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Our findings highlight the potential of this innovative therapeutic combination, suggesting a need for further investigations in this setting.
Authors
- Riham Suleiman (ORCID: https://orcid.org/0000-0002-3335-5022)
- Dawn Owen (ORCID: https://orcid.org/0000-0002-0538-3202)
- Harry E Fuentes (ORCID: https://orcid.org/0000-0002-7837-8359)
- Jesus Vera Aguilera
- Binav Baral
- Patrick W. McGarrah (ORCID: https://orcid.org/0000-0002-0664-9447)
- Katharine A. Price
- Thor R. Halfdanarson
Institutions
- Mayo Clinic (US)
- Essentia Health (US)
- WinnMed (US)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cnr2.70023
- Citations
- 5
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.17